English

PURE BIOSCIENCE, INC.

EDGAR

PURE Current report (8-K) · filed 2026-10-29

Annual consolidated revenue for 2026: about USD 2.315M, using the latest reported figures. The previous period, 2025, was about USD 2.198M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

657 thousand USD

2026 Q4 · USD

Exact inputs and evidence

Revenue: 2315000 USD Source
Revenue: 1658000 USD Source

Operating margin

-76.56%

2026 Q4 · %

Exact inputs and evidence

Operating Income: -2083000 USD Source
Operating Income: -1580000 USD Source
Revenue: 2315000 USD Source
Revenue: 1658000 USD Source

Operating cash flow

-414 thousand USD

2026 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -1738000 USD Source
Operating Cash Flow: -1324000 USD Source

Cash and cash equivalents: 569 thousand USD 2026-07-31 Source
Exact value

569000 USD
Long-term debt including current maturities: 6.6 million USD 2026-07-31 Source
Exact value

6602000 USD
Shares outstanding: 130 million shares 2026-07-31 Source
Exact value

130017569 shares

Reported share-count change

16.20% · 18.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

111886473 shares · 2025-07-31· Source
130017569 shares · 2026-07-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

2.31 million USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Revenue: 707000 USD · 2025-08-01 – 2025-10-31 Source
Revenue: 444000 USD · 2025-11-01 – 2026-01-31 Source
Revenue: 506000 USD · 2026-02-01 – 2026-04-30 Source
Revenue: 2315000 USD · 2025-08-01 – 2026-07-31 Source
Revenue: 1658000 USD · 2025-08-01 – 2026-04-30 Source

Net income

-2.48 million USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Net income: -464000 USD · 2025-08-01 – 2025-10-31 Source
Net income: -785000 USD · 2025-11-01 – 2026-01-31 Source
Net income: -624000 USD · 2026-02-01 – 2026-04-30 Source
Net income: -2483000 USD · 2025-08-01 – 2026-07-31 Source
Net income: -1873000 USD · 2025-08-01 – 2026-04-30 Source

Operating cash flow

-1.74 million USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Operating cash flow: -250000 USD · 2025-08-01 – 2025-10-31 Source
Operating cash flow: -856000 USD · 2025-08-01 – 2026-01-31 Source
Operating cash flow: -250000 USD · 2025-08-01 – 2025-10-31 Source
Operating cash flow: -1324000 USD · 2025-08-01 – 2026-04-30 Source
Operating cash flow: -856000 USD · 2025-08-01 – 2026-01-31 Source
Operating cash flow: -1738000 USD · 2025-08-01 – 2026-07-31 Source
Operating cash flow: -1324000 USD · 2025-08-01 – 2026-04-30 Source

Capital expenditure

93 thousand USD

2022-05-01 – 2023-04-30

Exact inputs and evidence

Capital expenditure: 81000 USD · 2021-08-01 – 2022-07-31 Source
Capital expenditure: 64000 USD · 2021-08-01 – 2022-04-30 Source
Capital expenditure: 37000 USD · 2022-08-01 – 2022-10-31 Source
Capital expenditure: 37000 USD · 2022-08-01 – 2023-01-31 Source
Capital expenditure: 37000 USD · 2022-08-01 – 2022-10-31 Source
Capital expenditure: 76000 USD · 2022-08-01 – 2023-04-30 Source
Capital expenditure: 37000 USD · 2022-08-01 – 2023-01-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2026-07-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2026-07-31
Operating income: 11 of 11 periods available· newest 2026-07-31
Net income: 11 of 11 periods available· newest 2026-07-31
Operating cash flow: 11 of 11 periods available· newest 2026-07-31
Capital expenditure: 8 of 11 periods available· newest 2023-07-31
Total assets: 10 of 11 periods available· newest 2026-07-31
Total liabilities: 10 of 11 periods available· newest 2026-07-31
Current assets: 10 of 11 periods available· newest 2026-07-31
Current liabilities: 10 of 11 periods available· newest 2026-07-31
Cash and cash equivalents: 10 of 11 periods available· newest 2026-07-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2026-07-31
Shares outstanding: 10 of 11 periods available· newest 2026-07-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+5.3%

Prior period

USD 2.2 million

2024-08-01 – 2025-07-31
Current period

USD 2.32 million

2025-08-01 – 2026-07-31

Exact inputs and evidence

2315000 − 2198000 = 117000 USD

2198000 USD · 2024-08-01 – 2025-07-31
Inspect prior input Prior source
2315000 USD · 2025-08-01 – 2026-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · PURE BIOSCIENCE, INC. · 2026-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Year-over-year change in Revenue: 117000 USD Concept: fundies:Revenue Period: 2025-08-01 to 2026-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2315000 USD (2025-08-01 to 2026-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1064366 Filing: 000149315226049272 Input fundies:Revenue: 2198000 USD (2024-08-01 to 2025-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1064795 Filing: 000149315226049272
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 84,000

Prior period

−USD 2.4 million

2024-08-01 – 2025-07-31
Current period

−USD 2.48 million

2025-08-01 – 2026-07-31

Exact inputs and evidence

-2483000 − -2399000 = -84000 USD

-2399000 USD · 2024-08-01 – 2025-07-31
Inspect prior input Prior source
-2483000 USD · 2025-08-01 – 2026-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PURE BIOSCIENCE, INC. · 2026-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Year-over-year change in Net income: -84000 USD Concept: fundies:NetIncome Period: 2025-08-01 to 2026-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2483000 USD (2025-08-01 to 2026-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1039977 Filing: 000149315226049272 Input fundies:NetIncome: -2399000 USD (2024-08-01 to 2025-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1007661 Filing: 000149315226049272
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 277,000

Prior period

−USD 2.02 million

2024-08-01 – 2025-07-31
Current period

−USD 1.74 million

2025-08-01 – 2026-07-31

Exact inputs and evidence

-1738000 − -2015000 = 277000 USD

-2015000 USD · 2024-08-01 – 2025-07-31
Inspect prior input Prior source
-1738000 USD · 2025-08-01 – 2026-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PURE BIOSCIENCE, INC. · 2026-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Year-over-year change in Operating cash flow: 277000 USD Concept: fundies:OperatingCashFlow Period: 2025-08-01 to 2026-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1738000 USD (2025-08-01 to 2026-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1040731 Filing: 000149315226049272 Input fundies:OperatingCashFlow: -2015000 USD (2024-08-01 to 2025-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1016430 Filing: 000149315226049272
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-08-01 – 2026-07-31

Revenue USD 2.32 million 100% of revenue
Cost of revenue USD 992,000 43% of revenue
Operating expenses USD 3.41 million 147% of revenue
Operating income −USD 2.08 million −90% of revenue
Tax, interest and other Derived USD 400,000 17% of revenue
Net income −USD 2.48 million −107% of revenue

Cash

Operating cash flow −USD 1.74 million −75% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 428% of revenue.
2018 Operating loss: operating costs were 497% of revenue.
2019 Operating loss: operating costs were 393% of revenue.
2020 100%
2021 Operating loss: operating costs were 162% of revenue.
2022 Operating loss: operating costs were 305% of revenue.
2023 Operating loss: operating costs were 311% of revenue.
2024 Operating loss: operating costs were 263% of revenue.
2025 Operating loss: operating costs were 203% of revenue.
2026 Operating loss: operating costs were 190% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2016-08-01 – 2017-07-31	1831000	7839000 Derived	-6008000	255000 Derived	-6263000	-4768000 Derived	Source 2016-08-01 – 2017-07-31: 1831000 USD Inspect Revenue Open source 2016-08-01 – 2017-07-31: -6008000 USD Inspect Operating Income Open source 2016-08-01 – 2017-07-31: -6263000 USD Inspect Net Income Open source 2016-08-01 – 2017-07-31: -4562000 USD Inspect Operating Cash Flow Open source 2016-08-01 – 2017-07-31: 206000 USD Inspect Capital Expenditure Open source
2018 2017-08-01 – 2018-07-31	1774000	8816000 Derived	-7042000	400000 Derived	-7442000	-3906000 Derived	Source 2017-08-01 – 2018-07-31: 1774000 USD Inspect Revenue Open source 2017-08-01 – 2018-07-31: -7042000 USD Inspect Operating Income Open source 2017-08-01 – 2018-07-31: -7442000 USD Inspect Net Income Open source 2017-08-01 – 2018-07-31: -3887000 USD Inspect Operating Cash Flow Open source 2017-08-01 – 2018-07-31: 19000 USD Inspect Capital Expenditure Open source
2019 2018-08-01 – 2019-07-31	1909000	7498000 Derived	-5589000	965000 Derived	-6554000	-2997000 Derived	Source 2018-08-01 – 2019-07-31: 1909000 USD Inspect Revenue Open source 2018-08-01 – 2019-07-31: -5589000 USD Inspect Operating Income Open source 2018-08-01 – 2019-07-31: -6554000 USD Inspect Net Income Open source 2018-08-01 – 2019-07-31: -2990000 USD Inspect Operating Cash Flow Open source 2018-08-01 – 2019-07-31: 7000 USD Inspect Capital Expenditure Open source
2020 2019-08-01 – 2020-07-31	6917000	6913000 Derived	4000	0 Derived	4000	611000 Derived	Source 2019-08-01 – 2020-07-31: 6917000 USD Inspect Revenue Open source 2019-08-01 – 2020-07-31: 4000 USD Inspect Operating Income Open source 2019-08-01 – 2020-07-31: 4000 USD Inspect Net Income Open source 2019-08-01 – 2020-07-31: 669000 USD Inspect Operating Cash Flow Open source 2019-08-01 – 2020-07-31: 58000 USD Inspect Capital Expenditure Open source
2021 2020-08-01 – 2021-07-31	3698000	6009000 Derived	-2311000	8000 Derived	-2319000	-1688000 Derived	Source 2020-08-01 – 2021-07-31: 3698000 USD Inspect Revenue Open source 2020-08-01 – 2021-07-31: -2311000 USD Inspect Operating Income Open source 2020-08-01 – 2021-07-31: -2319000 USD Inspect Net Income Open source 2020-08-01 – 2021-07-31: -1167000 USD Inspect Operating Cash Flow Open source 2020-08-01 – 2021-07-31: 521000 USD Inspect Capital Expenditure Open source
2022 2021-08-01 – 2022-07-31	1813000	5537000 Derived	-3724000	-233000 Derived	-3491000	-2499000 Derived	Source 2021-08-01 – 2022-07-31: 1813000 USD Inspect Revenue Open source 2021-08-01 – 2022-07-31: -3724000 USD Inspect Operating Income Open source 2021-08-01 – 2022-07-31: -3491000 USD Inspect Net Income Open source 2021-08-01 – 2022-07-31: -2418000 USD Inspect Operating Cash Flow Open source 2021-08-01 – 2022-07-31: 81000 USD Inspect Capital Expenditure Open source
2023 2022-08-01 – 2023-07-31	1871000	5814000 Derived	-3943000	18000 Derived	-3961000	-3311000 Derived	Source 2022-08-01 – 2023-07-31: 1871000 USD Inspect Revenue Open source 2022-08-01 – 2023-07-31: -3943000 USD Inspect Operating Income Open source 2022-08-01 – 2023-07-31: -3961000 USD Inspect Net Income Open source 2022-08-01 – 2023-07-31: -3278000 USD Inspect Operating Cash Flow Open source 2022-08-01 – 2023-07-31: 33000 USD Inspect Capital Expenditure Open source
2024 2023-08-01 – 2024-07-31	1955000	5146000 Derived	-3191000	159000 Derived	-3350000	Unavailable	Source 2023-08-01 – 2024-07-31: 1955000 USD Inspect Revenue Open source 2023-08-01 – 2024-07-31: -3191000 USD Inspect Operating Income Open source 2023-08-01 – 2024-07-31: -3350000 USD Inspect Net Income Open source 2023-08-01 – 2024-07-31: -2531000 USD Inspect Operating Cash Flow Open source
2025 2024-08-01 – 2025-07-31	2198000	4470000 Derived	-2272000	127000 Derived	-2399000	Unavailable	Source 2024-08-01 – 2025-07-31: 2198000 USD Inspect Revenue Open source 2024-08-01 – 2025-07-31: -2272000 USD Inspect Operating Income Open source 2024-08-01 – 2025-07-31: -2399000 USD Inspect Net Income Open source 2024-08-01 – 2025-07-31: -2015000 USD Inspect Operating Cash Flow Open source
2026 2025-08-01 – 2026-07-31	2315000	4398000 Derived	-2083000	400000 Derived	-2483000	Unavailable	Source 2025-08-01 – 2026-07-31: 2315000 USD Inspect Revenue Open source 2025-08-01 – 2026-07-31: -2083000 USD Inspect Operating Income Open source 2025-08-01 – 2026-07-31: -2483000 USD Inspect Net Income Open source 2025-08-01 – 2026-07-31: -1738000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.3M 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-07-31	Revenue	1831000	Revenue: 1831000 Open source
20182018-07-31	Revenue	1774000	Revenue: 1774000 Open source
20192019-07-31	Revenue	1909000	Revenue: 1909000 Open source
20202020-07-31	Revenue	6917000	Revenue: 6917000 Open source
20212021-07-31	Revenue	3698000	Revenue: 3698000 Open source
20222022-07-31	Revenue	1813000	Revenue: 1813000 Open source
20232023-07-31	Revenue	1871000	Revenue: 1871000 Open source
20242024-07-31	Revenue	1955000	Revenue: 1955000 Open source
20252025-07-31	Revenue	2198000	Revenue: 2198000 Open source
20262026-07-31	Revenue	2315000	Revenue: 2315000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

5.3% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-07-31	Year over year	No prior comparable period	Revenue: 1831000 Open source
20182018-07-31	Year over year	-3.1%	Revenue: 1774000 Open source Revenue: 1831000 Open source
20192019-07-31	Year over year	7.6%	Revenue: 1909000 Open source Revenue: 1774000 Open source
20202020-07-31	Year over year	262.3%	Revenue: 6917000 Open source Revenue: 1909000 Open source
20212021-07-31	Year over year	-46.5%	Revenue: 3698000 Open source Revenue: 6917000 Open source
20222022-07-31	Year over year	-51%	Revenue: 1813000 Open source Revenue: 3698000 Open source
20232023-07-31	Year over year	3.2%	Revenue: 1871000 Open source Revenue: 1813000 Open source
20242024-07-31	Year over year	4.5%	Revenue: 1955000 Open source Revenue: 1871000 Open source
20252025-07-31	Year over year	12.4%	Revenue: 2198000 Open source Revenue: 1955000 Open source
20262026-07-31	Year over year	5.3%	Revenue: 2315000 Open source Revenue: 2198000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -90% 2026

Net margin -107.3% 2026

Free cash flow margin -177% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-07-31	Operating margin	-328.1%	Operating Income: -6008000 Open source Revenue: 1831000 Open source
20182018-07-31	Operating margin	-397%	Operating Income: -7042000 Open source Revenue: 1774000 Open source
20192019-07-31	Operating margin	-292.8%	Operating Income: -5589000 Open source Revenue: 1909000 Open source
20202020-07-31	Operating margin	0.1%	Operating Income: 4000 Open source Revenue: 6917000 Open source
20212021-07-31	Operating margin	-62.5%	Operating Income: -2311000 Open source Revenue: 3698000 Open source
20222022-07-31	Operating margin	-205.4%	Operating Income: -3724000 Open source Revenue: 1813000 Open source
20232023-07-31	Operating margin	-210.7%	Operating Income: -3943000 Open source Revenue: 1871000 Open source
20242024-07-31	Operating margin	-163.2%	Operating Income: -3191000 Open source Revenue: 1955000 Open source
20252025-07-31	Operating margin	-103.4%	Operating Income: -2272000 Open source Revenue: 2198000 Open source
20262026-07-31	Operating margin	-90%	Operating Income: -2083000 Open source Revenue: 2315000 Open source
20172017-07-31	Net margin	-342.1%	Net Income: -6263000 Open source Revenue: 1831000 Open source
20182018-07-31	Net margin	-419.5%	Net Income: -7442000 Open source Revenue: 1774000 Open source
20192019-07-31	Net margin	-343.3%	Net Income: -6554000 Open source Revenue: 1909000 Open source
20202020-07-31	Net margin	0.1%	Net Income: 4000 Open source Revenue: 6917000 Open source
20212021-07-31	Net margin	-62.7%	Net Income: -2319000 Open source Revenue: 3698000 Open source
20222022-07-31	Net margin	-192.6%	Net Income: -3491000 Open source Revenue: 1813000 Open source
20232023-07-31	Net margin	-211.7%	Net Income: -3961000 Open source Revenue: 1871000 Open source
20242024-07-31	Net margin	-171.4%	Net Income: -3350000 Open source Revenue: 1955000 Open source
20252025-07-31	Net margin	-109.1%	Net Income: -2399000 Open source Revenue: 2198000 Open source
20262026-07-31	Net margin	-107.3%	Net Income: -2483000 Open source Revenue: 2315000 Open source
20172017-07-31	Free cash flow margin	-260.4%	Revenue: 1831000 Open source Operating Cash Flow: -4562000 Open source Capital Expenditure: 206000 Open source
20182018-07-31	Free cash flow margin	-220.2%	Revenue: 1774000 Open source Operating Cash Flow: -3887000 Open source Capital Expenditure: 19000 Open source
20192019-07-31	Free cash flow margin	-157%	Revenue: 1909000 Open source Operating Cash Flow: -2990000 Open source Capital Expenditure: 7000 Open source
20202020-07-31	Free cash flow margin	8.8%	Revenue: 6917000 Open source Operating Cash Flow: 669000 Open source Capital Expenditure: 58000 Open source
20212021-07-31	Free cash flow margin	-45.6%	Revenue: 3698000 Open source Operating Cash Flow: -1167000 Open source Capital Expenditure: 521000 Open source
20222022-07-31	Free cash flow margin	-137.8%	Revenue: 1813000 Open source Operating Cash Flow: -2418000 Open source Capital Expenditure: 81000 Open source
20232023-07-31	Free cash flow margin	-177%	Revenue: 1871000 Open source Operating Cash Flow: -3278000 Open source Capital Expenditure: 33000 Open source
20242024-07-31	Free cash flow margin	Not reported	Revenue: 1955000 Open source Operating Cash Flow: -2531000 Open source
20252025-07-31	Free cash flow margin	Not reported	Revenue: 2198000 Open source Operating Cash Flow: -2015000 Open source
20262026-07-31	Free cash flow margin	Not reported	Revenue: 2315000 Open source Operating Cash Flow: -1738000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1.7M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-07-31	Operating cash flow	-4562000	Operating Cash Flow: -4562000 Open source
20182018-07-31	Operating cash flow	-3887000	Operating Cash Flow: -3887000 Open source
20192019-07-31	Operating cash flow	-2990000	Operating Cash Flow: -2990000 Open source
20202020-07-31	Operating cash flow	669000	Operating Cash Flow: 669000 Open source
20212021-07-31	Operating cash flow	-1167000	Operating Cash Flow: -1167000 Open source
20222022-07-31	Operating cash flow	-2418000	Operating Cash Flow: -2418000 Open source
20232023-07-31	Operating cash flow	-3278000	Operating Cash Flow: -3278000 Open source
20242024-07-31	Operating cash flow	-2531000	Operating Cash Flow: -2531000 Open source
20252025-07-31	Operating cash flow	-2015000	Operating Cash Flow: -2015000 Open source
20262026-07-31	Operating cash flow	-1738000	Operating Cash Flow: -1738000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -3.3M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-07-31	Free cash flow	-4768000	Operating Cash Flow: -4562000 Open source Capital Expenditure: 206000 Open source
20182018-07-31	Free cash flow	-3906000	Operating Cash Flow: -3887000 Open source Capital Expenditure: 19000 Open source
20192019-07-31	Free cash flow	-2997000	Operating Cash Flow: -2990000 Open source Capital Expenditure: 7000 Open source
20202020-07-31	Free cash flow	611000	Operating Cash Flow: 669000 Open source Capital Expenditure: 58000 Open source
20212021-07-31	Free cash flow	-1688000	Operating Cash Flow: -1167000 Open source Capital Expenditure: 521000 Open source
20222022-07-31	Free cash flow	-2499000	Operating Cash Flow: -2418000 Open source Capital Expenditure: 81000 Open source
20232023-07-31	Free cash flow	-3311000	Operating Cash Flow: -3278000 Open source Capital Expenditure: 33000 Open source
20242024-07-31	Free cash flow	Unavailable	Operating Cash Flow: -2531000 Open source
20252025-07-31	Free cash flow	Unavailable	Operating Cash Flow: -2015000 Open source
20262026-07-31	Free cash flow	Unavailable	Operating Cash Flow: -1738000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

636.4% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-07-31	Liabilities / assets	66.3%	Total Liabilities: 2539000 Open source Total Assets: 3829000 Open source
20182018-07-31	Liabilities / assets	50.3%	Total Liabilities: 1294000 Open source Total Assets: 2575000 Open source
20192019-07-31	Liabilities / assets	38.4%	Total Liabilities: 742000 Open source Total Assets: 1932000 Open source
20202020-07-31	Liabilities / assets	23.9%	Total Liabilities: 1512000 Open source Total Assets: 6323000 Open source
20212021-07-31	Liabilities / assets	22.5%	Total Liabilities: 970000 Open source Total Assets: 4303000 Open source
20222022-07-31	Liabilities / assets	12.8%	Total Liabilities: 575000 Open source Total Assets: 4484000 Open source
20232023-07-31	Liabilities / assets	85.1%	Total Liabilities: 1553000 Open source Total Assets: 1825000 Open source
20242024-07-31	Liabilities / assets	450.1%	Total Liabilities: 3682000 Open source Total Assets: 818000 Open source
20252025-07-31	Liabilities / assets	583.6%	Total Liabilities: 6174000 Open source Total Assets: 1058000 Open source
20262026-07-31	Liabilities / assets	636.4%	Total Liabilities: 7592000 Open source Total Assets: 1193000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.27× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-07-31	Current assets / current liabilities	0.97×	Current Assets: 2459000 Open source Current Liabilities: 2528000 Open source
20182018-07-31	Current assets / current liabilities	1.14×	Current Assets: 1456000 Open source Current Liabilities: 1281000 Open source
20192019-07-31	Current assets / current liabilities	1.41×	Current Assets: 1041000 Open source Current Liabilities: 738000 Open source
20202020-07-31	Current assets / current liabilities	3.68×	Current Assets: 5566000 Open source Current Liabilities: 1512000 Open source
20212021-07-31	Current assets / current liabilities	3.3×	Current Assets: 3197000 Open source Current Liabilities: 970000 Open source
20222022-07-31	Current assets / current liabilities	6.72×	Current Assets: 3864000 Open source Current Liabilities: 575000 Open source
20232023-07-31	Current assets / current liabilities	3.02×	Current Assets: 1604000 Open source Current Liabilities: 532000 Open source
20242024-07-31	Current assets / current liabilities	1.1×	Current Assets: 805000 Open source Current Liabilities: 733000 Open source
20252025-07-31	Current assets / current liabilities	0.5×	Current Assets: 1047000 Open source Current Liabilities: 2113000 Open source
20262026-07-31	Current assets / current liabilities	0.27×	Current Assets: 1185000 Open source Current Liabilities: 4371000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2016-08-01 – 2017-07-31	−USD 6.26 million Exact value Exact value: -6263000 USD 2016-08-01 – 2017-07-31: -6263000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2017-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -6263000 USD Concept: fundies:NetIncome Period: 2016-08-01 to 2017-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2017-07-31&surface=latest&period_type=duration&start=2016-08-01&unit=USD&dimensions= Input fundies:NetIncome: -6263000 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315218014849/pure-20180731.xml#98533 Filing: 000149315218014849 The citation records this snapshot. The page link may show a newer release later.	−USD 4.56 million Exact value Exact value: -4562000 USD 2016-08-01 – 2017-07-31: -4562000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2017-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -4562000 USD Concept: fundies:OperatingCashFlow Period: 2016-08-01 to 2017-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2017-07-31&surface=latest&period_type=duration&start=2016-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4562000 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315218014849/pure-20180731.xml#102696 Filing: 000149315218014849 The citation records this snapshot. The page link may show a newer release later.	USD 206,000 Exact value Exact value: 206000 USD 2016-08-01 – 2017-07-31: 206000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2017-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 206000 USD Concept: fundies:CapitalExpenditure Period: 2016-08-01 to 2017-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2017-07-31&surface=latest&period_type=duration&start=2016-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 206000 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315218014849/pure-20180731.xml#103391 Filing: 000149315218014849 The citation records this snapshot. The page link may show a newer release later.	−USD 4.77 million Calculation and evidence -4562000 − 206000 USD Exact free cash flow: -4768000 USD 2016-08-01 – 2017-07-31: -4562000 USD · Inspect Operating Cash Flow · Source 2016-08-01 – 2017-07-31: 206000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2017-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: -4768000 USD Concept: free-cash-flow Period: 2016-08-01 to 2017-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4562000 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315218014849/pure-20180731.xml#102696 Filing: 000149315218014849 Input fundies:CapitalExpenditure: 206000 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315218014849/pure-20180731.xml#103391 Filing: 000149315218014849 The citation records this snapshot. The page link may show a newer release later.
2018 2017-08-01 – 2018-07-31	−USD 7.44 million Exact value Exact value: -7442000 USD 2017-08-01 – 2018-07-31: -7442000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2018-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -7442000 USD Concept: fundies:NetIncome Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2018-07-31&surface=latest&period_type=duration&start=2017-08-01&unit=USD&dimensions= Input fundies:NetIncome: -7442000 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315219016126/pure-20190731.xml#89020 Filing: 000149315219016126 The citation records this snapshot. The page link may show a newer release later.	−USD 3.89 million Exact value Exact value: -3887000 USD 2017-08-01 – 2018-07-31: -3887000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2018-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -3887000 USD Concept: fundies:OperatingCashFlow Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2018-07-31&surface=latest&period_type=duration&start=2017-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3887000 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315219016126/pure-20190731.xml#92357 Filing: 000149315219016126 The citation records this snapshot. The page link may show a newer release later.	USD 19,000 Exact value Exact value: 19000 USD 2017-08-01 – 2018-07-31: 19000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2018-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 19000 USD Concept: fundies:CapitalExpenditure Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2018-07-31&surface=latest&period_type=duration&start=2017-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19000 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315219016126/pure-20190731.xml#93454 Filing: 000149315219016126 The citation records this snapshot. The page link may show a newer release later.	−USD 3.91 million Calculation and evidence -3887000 − 19000 USD Exact free cash flow: -3906000 USD 2017-08-01 – 2018-07-31: -3887000 USD · Inspect Operating Cash Flow · Source 2017-08-01 – 2018-07-31: 19000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2018-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: -3906000 USD Concept: free-cash-flow Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3887000 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315219016126/pure-20190731.xml#92357 Filing: 000149315219016126 Input fundies:CapitalExpenditure: 19000 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315219016126/pure-20190731.xml#93454 Filing: 000149315219016126 The citation records this snapshot. The page link may show a newer release later.
2019 2018-08-01 – 2019-07-31	−USD 6.55 million Exact value Exact value: -6554000 USD 2018-08-01 – 2019-07-31: -6554000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2019-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -6554000 USD Concept: fundies:NetIncome Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2019-07-31&surface=latest&period_type=duration&start=2018-08-01&unit=USD&dimensions= Input fundies:NetIncome: -6554000 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315220019153/pure-20200731.xml#89191 Filing: 000149315220019153 The citation records this snapshot. The page link may show a newer release later.	−USD 2.99 million Exact value Exact value: -2990000 USD 2018-08-01 – 2019-07-31: -2990000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2019-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -2990000 USD Concept: fundies:OperatingCashFlow Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2019-07-31&surface=latest&period_type=duration&start=2018-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2990000 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315220019153/pure-20200731.xml#118724 Filing: 000149315220019153 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2018-08-01 – 2019-07-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2019-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2019-07-31&surface=latest&period_type=duration&start=2018-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315220019153/pure-20200731.xml#91758 Filing: 000149315220019153 The citation records this snapshot. The page link may show a newer release later.	−USD 3 million Calculation and evidence -2990000 − 7000 USD Exact free cash flow: -2997000 USD 2018-08-01 – 2019-07-31: -2990000 USD · Inspect Operating Cash Flow · Source 2018-08-01 – 2019-07-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2019-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: -2997000 USD Concept: free-cash-flow Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2990000 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315220019153/pure-20200731.xml#118724 Filing: 000149315220019153 Input fundies:CapitalExpenditure: 7000 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315220019153/pure-20200731.xml#91758 Filing: 000149315220019153 The citation records this snapshot. The page link may show a newer release later.
2020 2019-08-01 – 2020-07-31	USD 4,000 Exact value Exact value: 4000 USD 2019-08-01 – 2020-07-31: 4000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2020-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: 4000 USD Concept: fundies:NetIncome Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2020-07-31&surface=latest&period_type=duration&start=2019-08-01&unit=USD&dimensions= Input fundies:NetIncome: 4000 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315221026623/pure-20210731.xml#71727 Filing: 000149315221026623 The citation records this snapshot. The page link may show a newer release later.	USD 669,000 Exact value Exact value: 669000 USD 2019-08-01 – 2020-07-31: 669000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2020-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: 669000 USD Concept: fundies:OperatingCashFlow Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2020-07-31&surface=latest&period_type=duration&start=2019-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 669000 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315221026623/pure-20210731.xml#91040 Filing: 000149315221026623 The citation records this snapshot. The page link may show a newer release later.	USD 58,000 Exact value Exact value: 58000 USD 2019-08-01 – 2020-07-31: 58000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2020-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 58000 USD Concept: fundies:CapitalExpenditure Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2020-07-31&surface=latest&period_type=duration&start=2019-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 58000 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315221026623/pure-20210731.xml#90673 Filing: 000149315221026623 The citation records this snapshot. The page link may show a newer release later.	USD 611,000 Calculation and evidence 669000 − 58000 USD Exact free cash flow: 611000 USD 2019-08-01 – 2020-07-31: 669000 USD · Inspect Operating Cash Flow · Source 2019-08-01 – 2020-07-31: 58000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2020-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: 611000 USD Concept: free-cash-flow Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 669000 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315221026623/pure-20210731.xml#91040 Filing: 000149315221026623 Input fundies:CapitalExpenditure: 58000 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315221026623/pure-20210731.xml#90673 Filing: 000149315221026623 The citation records this snapshot. The page link may show a newer release later.
2021 2020-08-01 – 2021-07-31	−USD 2.32 million Exact value Exact value: -2319000 USD 2020-08-01 – 2021-07-31: -2319000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2021-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -2319000 USD Concept: fundies:NetIncome Period: 2020-08-01 to 2021-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2021-07-31&surface=latest&period_type=duration&start=2020-08-01&unit=USD&dimensions= Input fundies:NetIncome: -2319000 USD (2020-08-01 to 2021-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315222029844/form10-k.htm#957787 Filing: 000149315222029844 The citation records this snapshot. The page link may show a newer release later.	−USD 1.17 million Exact value Exact value: -1167000 USD 2020-08-01 – 2021-07-31: -1167000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2021-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -1167000 USD Concept: fundies:OperatingCashFlow Period: 2020-08-01 to 2021-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2021-07-31&surface=latest&period_type=duration&start=2020-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1167000 USD (2020-08-01 to 2021-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315222029844/form10-k.htm#968847 Filing: 000149315222029844 The citation records this snapshot. The page link may show a newer release later.	USD 521,000 Exact value Exact value: 521000 USD 2020-08-01 – 2021-07-31: 521000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2021-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 521000 USD Concept: fundies:CapitalExpenditure Period: 2020-08-01 to 2021-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2021-07-31&surface=latest&period_type=duration&start=2020-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 521000 USD (2020-08-01 to 2021-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315222029844/form10-k.htm#970549 Filing: 000149315222029844 The citation records this snapshot. The page link may show a newer release later.	−USD 1.69 million Calculation and evidence -1167000 − 521000 USD Exact free cash flow: -1688000 USD 2020-08-01 – 2021-07-31: -1167000 USD · Inspect Operating Cash Flow · Source 2020-08-01 – 2021-07-31: 521000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2021-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: -1688000 USD Concept: free-cash-flow Period: 2020-08-01 to 2021-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1167000 USD (2020-08-01 to 2021-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315222029844/form10-k.htm#968847 Filing: 000149315222029844 Input fundies:CapitalExpenditure: 521000 USD (2020-08-01 to 2021-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315222029844/form10-k.htm#970549 Filing: 000149315222029844 The citation records this snapshot. The page link may show a newer release later.
2022 2021-08-01 – 2022-07-31	−USD 3.49 million Exact value Exact value: -3491000 USD 2021-08-01 – 2022-07-31: -3491000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2022-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -3491000 USD Concept: fundies:NetIncome Period: 2021-08-01 to 2022-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2022-07-31&surface=latest&period_type=duration&start=2021-08-01&unit=USD&dimensions= Input fundies:NetIncome: -3491000 USD (2021-08-01 to 2022-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315223038673/form10-k.htm#988247 Filing: 000149315223038673 The citation records this snapshot. The page link may show a newer release later.	−USD 2.42 million Exact value Exact value: -2418000 USD 2021-08-01 – 2022-07-31: -2418000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2022-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -2418000 USD Concept: fundies:OperatingCashFlow Period: 2021-08-01 to 2022-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2022-07-31&surface=latest&period_type=duration&start=2021-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2418000 USD (2021-08-01 to 2022-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315223038673/form10-k.htm#999741 Filing: 000149315223038673 The citation records this snapshot. The page link may show a newer release later.	USD 81,000 Exact value Exact value: 81000 USD 2021-08-01 – 2022-07-31: 81000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2022-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 81000 USD Concept: fundies:CapitalExpenditure Period: 2021-08-01 to 2022-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2022-07-31&surface=latest&period_type=duration&start=2021-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 81000 USD (2021-08-01 to 2022-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315223038673/form10-k.htm#1001314 Filing: 000149315223038673 The citation records this snapshot. The page link may show a newer release later.	−USD 2.5 million Calculation and evidence -2418000 − 81000 USD Exact free cash flow: -2499000 USD 2021-08-01 – 2022-07-31: -2418000 USD · Inspect Operating Cash Flow · Source 2021-08-01 – 2022-07-31: 81000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2022-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: -2499000 USD Concept: free-cash-flow Period: 2021-08-01 to 2022-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2418000 USD (2021-08-01 to 2022-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315223038673/form10-k.htm#999741 Filing: 000149315223038673 Input fundies:CapitalExpenditure: 81000 USD (2021-08-01 to 2022-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315223038673/form10-k.htm#1001314 Filing: 000149315223038673 The citation records this snapshot. The page link may show a newer release later.
2023 2022-08-01 – 2023-07-31	−USD 3.96 million Exact value Exact value: -3961000 USD 2022-08-01 – 2023-07-31: -3961000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2023-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -3961000 USD Concept: fundies:NetIncome Period: 2022-08-01 to 2023-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2023-07-31&surface=latest&period_type=duration&start=2022-08-01&unit=USD&dimensions= Input fundies:NetIncome: -3961000 USD (2022-08-01 to 2023-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315224042939/form10-k.htm#1116905 Filing: 000149315224042939 The citation records this snapshot. The page link may show a newer release later.	−USD 3.28 million Exact value Exact value: -3278000 USD 2022-08-01 – 2023-07-31: -3278000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2023-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -3278000 USD Concept: fundies:OperatingCashFlow Period: 2022-08-01 to 2023-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2023-07-31&surface=latest&period_type=duration&start=2022-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3278000 USD (2022-08-01 to 2023-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315224042939/form10-k.htm#1139457 Filing: 000149315224042939 The citation records this snapshot. The page link may show a newer release later.	USD 33,000 Exact value Exact value: 33000 USD 2022-08-01 – 2023-07-31: 33000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PURE BIOSCIENCE, INC. · 2023-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Capital Expenditure: 33000 USD Concept: fundies:CapitalExpenditure Period: 2022-08-01 to 2023-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ACapitalExpenditure&period=2023-07-31&surface=latest&period_type=duration&start=2022-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 33000 USD (2022-08-01 to 2023-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315224042939/form10-k.htm#1143024 Filing: 000149315224042939 The citation records this snapshot. The page link may show a newer release later.	−USD 3.31 million Calculation and evidence -3278000 − 33000 USD Exact free cash flow: -3311000 USD 2022-08-01 – 2023-07-31: -3278000 USD · Inspect Operating Cash Flow · Source 2022-08-01 – 2023-07-31: 33000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PURE BIOSCIENCE, INC. · 2023-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Free cash flow: -3311000 USD Concept: free-cash-flow Period: 2022-08-01 to 2023-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3278000 USD (2022-08-01 to 2023-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315224042939/form10-k.htm#1139457 Filing: 000149315224042939 Input fundies:CapitalExpenditure: 33000 USD (2022-08-01 to 2023-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315224042939/form10-k.htm#1143024 Filing: 000149315224042939 The citation records this snapshot. The page link may show a newer release later.
2024 2023-08-01 – 2024-07-31	−USD 3.35 million Exact value Exact value: -3350000 USD 2023-08-01 – 2024-07-31: -3350000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2024-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -3350000 USD Concept: fundies:NetIncome Period: 2023-08-01 to 2024-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2024-07-31&surface=latest&period_type=duration&start=2023-08-01&unit=USD&dimensions= Input fundies:NetIncome: -3350000 USD (2023-08-01 to 2024-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315225020065/form10-k.htm#980752 Filing: 000149315225020065 The citation records this snapshot. The page link may show a newer release later.	−USD 2.53 million Exact value Exact value: -2531000 USD 2023-08-01 – 2024-07-31: -2531000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2024-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -2531000 USD Concept: fundies:OperatingCashFlow Period: 2023-08-01 to 2024-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2024-07-31&surface=latest&period_type=duration&start=2023-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2531000 USD (2023-08-01 to 2024-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315225020065/form10-k.htm#990111 Filing: 000149315225020065 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2024-08-01 – 2025-07-31	−USD 2.4 million Exact value Exact value: -2399000 USD 2024-08-01 – 2025-07-31: -2399000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2025-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -2399000 USD Concept: fundies:NetIncome Period: 2024-08-01 to 2025-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2025-07-31&surface=latest&period_type=duration&start=2024-08-01&unit=USD&dimensions= Input fundies:NetIncome: -2399000 USD (2024-08-01 to 2025-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1007661 Filing: 000149315226049272 The citation records this snapshot. The page link may show a newer release later.	−USD 2.02 million Exact value Exact value: -2015000 USD 2024-08-01 – 2025-07-31: -2015000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2025-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -2015000 USD Concept: fundies:OperatingCashFlow Period: 2024-08-01 to 2025-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2025-07-31&surface=latest&period_type=duration&start=2024-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2015000 USD (2024-08-01 to 2025-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1016430 Filing: 000149315226049272 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2026 2025-08-01 – 2026-07-31	−USD 2.48 million Exact value Exact value: -2483000 USD 2025-08-01 – 2026-07-31: -2483000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PURE BIOSCIENCE, INC. · 2026-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Net Income: -2483000 USD Concept: fundies:NetIncome Period: 2025-08-01 to 2026-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3ANetIncome&period=2026-07-31&surface=latest&period_type=duration&start=2025-08-01&unit=USD&dimensions= Input fundies:NetIncome: -2483000 USD (2025-08-01 to 2026-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1039977 Filing: 000149315226049272 The citation records this snapshot. The page link may show a newer release later.	−USD 1.74 million Exact value Exact value: -1738000 USD 2025-08-01 – 2026-07-31: -1738000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PURE BIOSCIENCE, INC. · 2026-07-31 PURE BIOSCIENCE, INC. (edgar:1006028) Operating Cash Flow: -1738000 USD Concept: fundies:OperatingCashFlow Period: 2025-08-01 to 2026-07-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006028/explain?concept=fundies%3AOperatingCashFlow&period=2026-07-31&surface=latest&period_type=duration&start=2025-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1738000 USD (2025-08-01 to 2026-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/form10-k.htm#1040731 Filing: 000149315226049272 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

174 filings · 3,984 latest values · 3,984 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001006028, 1006028, PURE, edgar:1006028, pure

Also known as INNOVATIVE MEDICAL SERVICES, PURE Bioscience, Inc., PURE BIOSCIENCE, PURE BIOSCIENCE, INC., PURE Bioscience, Inc.

PURE BIOSCIENCE, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2026 2025-08-01 – 2026-07-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation